乾癬治療薬のパイプライン分析

【英語タイトル】Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

P&S Market Researchが出版した調査資料(PSM802143)・商品コード:PSM802143
・発行会社(調査会社):P&S Market Research
・発行日:2017年10月1日
・ページ数:301
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD8,000 ⇒換算¥864,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of the skin, causing patches of psoriasis to appear. There are five types of psoriasis namely, plaque psoriasis or psoriasis vulgaris, guttate psoriasis, inverse psoriasis or flexural psoriasis or intertriginous psoriasis, pustular psoriasis, and erythrodermic or exfoliative psoriasis.
Insights on pipeline segments

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by topical route.

PAD technology platform for psoriasis drug development

MC2 Therapeutics A/S is using PAD technology platform for the development of MC2-01 for the treatment of psoriasis. PAD technology platform offers a number of unique advantages in the development of new topical drugs. PAD vehicles are special made oil-in-water dispersions in which the internal oil phase is stabilized by encapsulation in a thin yet robust aqueous film of surfactants.

Various collaborations for psoriasis drug development

Boehringer Ingelheim GmbH and AbbVie, Inc. entered in a worldwide agreement to develop and commercialize BI 655066, for the treatment of psoriasis.
Some of the key players developing drugs for the treatment of psoriasis include Amgen Inc., Maruho Co., Ltd., Boehringer Ingelheim GmbH and others.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Molecule Type

1.3.3. Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.1.1 Signs and Symptoms

4.1.2 Pathophysiology

4.1.3 Epidemiology

4.1.4 Diagnosis

4.1.5 Treatment

4.2 Key Drivers

4.3 Key Barriers

4.4 Psoriasis Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Psoriasis Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase II: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Clinical Trials

5.3.4 Clinical Results

5.3.5 Strategic Development

5.3.6 Designation

5.3.7 Grants

5.3.8 Patent

5.3.9 Technology

5.4 Phase I: Drug profiles

5.4.1 Pre-Clinical Study

5.4.2 Pre-Clinical Results

5.4.3 Clinical Trials

5.4.4 Clinical Results

5.4.5 Strategic Development

5.4.6 Designation

5.4.7 Grants

5.4.8 Patent

5.4.9 Technology

5.5 Pre-Clinical: Drug profiles

5.6 Discovery: Drug profiles

5.7 Unknown: Drug profiles

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Psoriasis Therapeutics Pipeline

7.2 SWOT Analysis of Psoriasis Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

PIPELINE ANALYSIS OF PSORIASIS THERAPEUTICS, BY COMPANY (2017)

DESCRIPTION OF FILED DRUG CANDIDATES

CLINICAL TRIALS OF FILED DRUG CANDIDATES

DESCRIPTION OF PHASE III DRUG CANDIDATES

CLINICAL TRIALS OF PHASE III DRUG CANDIDATES

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

DESCRIPTION OF DISCOVERY DRUG CANDIDATES

DESCRIPTION OF UNKNOWN DRUG CANDIDATES

COMPANIES- AT A GLANCE

LIST OF FIGURES

RESEARCH METHODOLOGY

SPLIT OF PRIMARY AND SECONDARY RESEARCH

BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

PATHOPHYSIOLOGY OF PSORIASIS

PSORIASIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

PSORIASIS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

PSORIASIS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING FOR PSORIASIS THERAPEUTICS PIPELINE

SWOT ANALYSIS OF PSORIASIS THERAPEUTICS PIPELINE



【レポートのキーワード】

乾癬

★調査レポート[乾癬治療薬のパイプライン分析] (コード:PSM802143)販売に関する免責事項を必ずご確認ください。
★調査レポート[乾癬治療薬のパイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆